NEW YORK (GenomeWeb) – ERS Genomics today announced that it has non-exclusively licensed patents related to CRISPR-Cas9 genome-editing technology to Regeneron Pharmaceuticals for use in drug discovery and development.

Specific terms of the deal were not disclosed.

ERS was founded to provide broad access to the intellectual property, which is based on the research of Emmanuelle Charpentier from the Hannover Medical School in Germany and Umea University in Sweden.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.